NIMI
ALXN

Natixis Investment Managers International’s Alexion Pharmaceuticals ALXN Stock Holding History

Natixis Investment Managers International’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,703
Closed -$376K – 624
2018
Q3 		$376K Buy
2,703
+897
+50% +$113K 0.02% 528
2018
Q2 		$224K Buy
1,806
+956
+112% +$112K 0.01% 561
2018
Q1 		$95K Buy
850
+808
+1,924% +$96.6K 0.01% 420
2017
Q4 		$5K Hold
42
– – ﹤0.01% 147
2017
Q3 		$6K Hold
42
– – ﹤0.01% 397
2017
Q2 		$5K Sell
42
-7,958
-99% -$926K ﹤0.01% 401
2017
Q1 		$970K Sell
8,000
-49
-0.6% -$6.32K 0.09% 179
2016
Q4 		$984K Buy
+8,049
New +$985K 0.09% 165
2016
Q2 		– Sell
-1,168
Closed -$163K – 409
2016
Q1 		$163K Sell
1,168
-2,086
-64% -$306K 0.02% 336
2015
Q4 		$621K Buy
3,254
+2,086
+179% +$364K 0.08% 123
2015
Q3 		$183K Buy
1,168
+256
+28% +$46.7K 0.02% 312
2015
Q2 		$165K Buy
+912
New +$157K 0.02% 326
2015
Q1 		– Sell
-852
Closed -$158K – 458
2014
Q4 		$158K Buy
+852
New +$158K 0.02% 290

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis Investment Managers International's ALXN Position: Q4 2018 in Review

Natixis Investment Managers International sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 2,703 shares — an estimated $376K sold.

Natixis Investment Managers International first reported a position in ALXN in Q4 2014 and held it in 13 quarters. The position peaked at $984K in Q4 2016. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Natixis Investment Managers International reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Natixis Investment Managers International sold 2,703 Alexion Pharmaceuticals shares in Q4 2018, an estimated $376K.
  • Natixis Investment Managers International first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • Natixis Investment Managers International's Alexion Pharmaceuticals position peaked at $984K in Q4 2016.
  • 609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Natixis Investment Managers International's 13F filing for Q4 2018, filed 14 Feb 2019.